![]() |
市场调查报告书
商品编码
1374889
全球腕隧道释放系统市场 - 2023-2030Global Carpal Tunnel Release System Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
腕隧道鬆解系统是一种医疗程序和一套用于治疗腕管综合症(CTS)的技术。 CTS 是一种经常发生的疾病,从前臂延伸到手部的正中神经在穿过手腕中称为腕管的狭窄通道时受到压缩或挤压。
用于治疗腕隧道症候群(CTS)的主要手术方法有两种:开放式腕管鬆解系统和内视镜腕管鬆解系统。此外,腕管综合症的盛行率不断上升、腕管松解和肌腱病治疗的新方法以及市场参与者不断增加的医学教育培训计划是预计在预测期内推动市场的因素。
腕隧道症候群患者常会出现肌腱疾病,这是一种常见疾病。腕隧道释放系统最近得到了改进,除了释放腕管之外还可以解决肌腱病问题。例如,梅奥诊所是为数不多的提供超音波引导腕管松解干预的手部中心之一,这是一种先进的治疗方法。超音波导引腕管鬆解术 (TCTR) 是一种较新的微创技术,不需要大切口。与传统的开放式CTR手术相比,这种方法显着减少了对周围组织的损伤,从而减少了术后疼痛并加快了患者的恢復时间。
超音波引导的使用是 TCTR 的一个重要方面。该技术使外科医生能够即时查看腕管的内部结构,确保磨料线的准确放置。因此,降低了对周围结构造成伤害的风险,并且该过程变得更加有效和安全。
此外,TCTR通常在门诊进行,患者可以在手术当天回家。这不仅增加了患者的便利性,也减少了医疗费用。 TCTR 是传统 CTR 的一种侵入性较小的替代方案,这意味着患者的恢復时间可能会更快。这可以使许多人更早恢復日常活动,并且可能需要更少的术后復原。
因此,该手术变得更加广泛和精细,可能会影响腕管松解术的研究和创新,从而导致技术和工艺的进一步改进。因此,由于上述因素,预计市场在预测期内将继续成长。
腕隧道释放系统的成本非常高,尤其是 Microaire 81014 等微创释放系统,约 2,500 美元。这种高昂的成本为病患和医疗机构都带来了重大问题。由于费用高昂,许多患者不愿寻求腕管综合症的治疗,这可能导致长期疼痛和残疾。
此外,预算有限地区的医疗机构可能无法负担这些昂贵的系统,这限制了先进腕管松解技术的使用。因此,与这些系统相关的高成本导致市场渗透率下降,并阻碍其广泛采用,最终影响受影响地区的患者护理和医疗基础设施。
Carpal tunnel release system is a medical procedure and a set of techniques that are used to treat carpal tunnel syndrome (CTS). CTS is a frequently occurring condition in which the median nerve, running from the forearm into the hand, gets compressed or squeezed as it passes through a narrow passageway called the carpal tunnel in the wrist.
There are two main surgical approaches used to treat carpal tunnel syndrome (CTS) open carpal tunnel release system and endoscopic carpal tunnel release system. Furthermore, the increasing prevalence of carpal tunnel syndrome, new approaches to carpal tunnel release and treatment of tendinopathy, and rising medical education training programs by the market players are the factors expected to drive the market over the forecast period.
Patients with carpal tunnel syndrome often experience tendinopathy, a common condition. Carpal tunnel release systems have recently been improved to address tendinopathy in addition to releasing the carpal tunnel. For instance, the Mayo Clinic is one of the few hand centers that provide ultrasound-guided intervention for carpal tunnel release, which is an advanced treatment. Thread Ultrasound-Guided Carpal Tunnel Release (TCTR) is a newer, minimally invasive technique that does not require large incisions. Compared to traditional open CTR procedures, this approach significantly reduces the damage to the surrounding tissues, resulting in less postoperative pain and faster recovery times for patients.
The use of ultrasound guidance is a crucial aspect of TCTR. This technology enables surgeons to view the internal structures of the carpal tunnel in real time, ensuring accurate and precise placement of the abrasive thread. As a result, the risk of harm to surrounding structures is reduced, and the procedure becomes more effective and safe.
In addition, TCTR is usually done on an outpatient basis, allowing patients to return home on the same day of the operation. This not only increases patient convenience but also results in reduced healthcare expenses. TCTR is a less invasive alternative to traditional CTR, which means that recovery times may be faster for patients. This can enable many individuals to resume their daily activities earlier and potentially require less postoperative rehabilitation.
Therefore, the procedure becomes more widespread and refined, it may influence research and innovation in carpal tunnel release, leading to further improvements in techniques and technologies. Thus, owing to the above factors, the market is expected to drive over the forecast period.
The cost of carpal tunnel release systems, especially minimally invasive ones like the Microaire 81014, is very high around $2,500. This high cost poses a significant problem for both patients and healthcare facilities. Many patients are deterred from seeking treatment for carpal tunnel syndrome due to the high cost, which can lead to prolonged pain and disability.
Additionally, healthcare facilities in regions with limited budgets may not be able to afford these expensive systems, which limits access to advanced carpal tunnel release techniques. Therefore, the high costs associated with these systems have led to reduced market penetration and hindered their widespread adoption, ultimately impacting patient care and healthcare infrastructure in affected regions.
The global carpal tunnel release system market is segmented based on product type, surgical approach, technology, end-user and region.
Carpal tunnel syndrome is a common condition where the median nerve in the wrist is compressed and causes discomfort. Endoscopic Carpal Tunnel Release Systems (ECTRS) are minimally invasive surgical tools designed to treat this condition. ECTRS involves the use of a small endoscope, which is a thin tube with a camera, and specialized instruments to release the transverse carpal ligament. This procedure helps to alleviate the pressure on the median nerve and provides relief from the symptoms of carpal tunnel syndrome.
Moreover, it leads to smaller incisions, reduced post-operative pain, faster recovery times, and less scarring when compared to traditional open surgery. ECTRS also enables patients to return to their daily activities and work more quickly, making it a more appealing choice for those searching for a faster and less disruptive remedy for carpal tunnel syndrome.
In addition, ECTRS enables patients to return to their daily activities and work sooner, making it an attractive option for individuals seeking a faster and less disruptive treatment for carpal tunnel syndrome. Furthermore, increasing preference for minimally invasive procedures, increasing the prevalence of carpal tunnel syndrome, and technological advancements are the factors expected to drive the market segment over the forecast period.
For instance, the traditional method for treating this condition involved open surgery, which required a larger incision in the wrist to access and release the compressed median nerve. However, with the advancement of minimally invasive techniques, endoscopic carpal tunnel release has become more popular.
The Endotrac Endoscopic Carpal Tunnel Release System by Stryker is a medical device that enables minimally invasive surgical treatment of carpal tunnel syndrome, a common condition where the median nerve in the wrist is compressed.
Therefore, endoscopic carpal tunnel release systems have gained more popularity among patients and healthcare providers as compared to traditional open surgery in treating carpal tunnel syndrome. This trend reflects the broader shift in medicine toward minimally invasive procedures whenever feasible, as they tend to offer better patient outcomes and experiences. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.
North America Accounted for Approximately 39.2% of the Market Share in 2022
North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of carpal tunnel syndrome, increasing adoption of surgical intervention, the introduction of new products, and rising healthcare expenditure.
For instance, according to the Mayo Foundation for Medical Education and Research (MFMER) Article, Carpal tunnel syndrome is a common condition that affects many people, and it is estimated that 71% of patients undergo surgical intervention as their primary treatment.
The cost of medical care for carpal tunnel syndrome in the United States is approximately $2 billion per year, and the median time lost from work is just under 30 days. The surgical treatment usually involves an open procedure, while the endoscopic approach is often associated with less postoperative pain and a faster return to work.
The major global players in the carpal tunnel release system market include: Arthrex, Inc., MicroAire Surgical Instruments, LLC, Trice Medical, Smith & Nephew plc, Integra LifeSciences Corporation, Stryker Corporation, Innomed, Inc., A.M. Surgical, Inc., Medical Designs, LLC, and Sonex Health Inc. among others.
The COVID-19 pandemic has negatively impacted the carpal tunnel release system market. Due to the COVID-19 pandemic, healthcare facilities have been focusing their resources on treating infected patients while trying to limit the spread of the virus. As a result, many elective surgeries, such as carpal tunnel release procedures, have been postponed or canceled. This temporary delay in surgeries has caused a decline in demand for carpal tunnel release systems.
The pandemic has caused a prominent rise in remote consultations and telemedicine. Therefore, some patients with mild to moderate carpal tunnel syndrome might have chosen non-surgical treatments and remote consultations instead of surgery, which could have impacted the demand for carpal tunnel release systems. The pandemic has also highlighted the significance of safety in healthcare settings. This focus on safety may have accelerated the adoption of minimally invasive techniques such as endoscopic carpal tunnel release systems, which provide advantages such as reduced hospital stays and faster recovery times.
The global carpal tunnel release system market report would provide approximately 61 tables, 56 figures, and 186 Pages.
LIST NOT EXHAUSTIVE